SYFOVRE®
(pegcetacoplan injection)
15 mg / 0.1 mL

Join Us for a Discussion on:

SYFOVRE for GA Secondary to AMD

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

SELECT SAFETY INFORMATION

SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation.

Please see additional Important Safety Information on next page.

PROGRAM OVERVIEW

Join us to participate in a peer-to-peer educational opportunity about SYFOVRE for GA. This session will focus on SYFOVRE, the first FDA-approved therapy for the treatment of GA. During this program, we will discuss:

- SYFOVRE clinical data
- SYFOVRE dosing and administration
- SYFOVRE safety information

PROGRAM DETAILS

Tuesday, September 26, 2023
07:00 - 08:00 PM Eastern

The Capital Grille
1861 International Dr
MC LEAN, Virginia 22102

Jonathan Jonisch, MD

REGISTER HERE

Reserve your spot by registering at Registration.apellissb.com and enter the program code APLS1333 scanning the QR code to the right, or by contacting your Apellis Representative

This program is intended for US eyecare professionals only. Guests and spouses may not attend this program. This is a promotional program, and no CME credits are offered. A meal will be provided during this educational program. In accordance with the Federal Physician Payment Sunshine Statute and any applicable state reporting laws, the value of the food and beverage provided and your national provider identity may be disclosed to CMS and any applicable state agencies. Attendees arriving after the program start time will only be provided a meal if they are present for the majority of the speaker's educational presentation.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

WARNINGS AND PRECAUTIONS

- **Endophthalmitis and Retinal Detachments**
  - Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
- **Neovascular AMD**
  - In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
- **Intraocular Inflammation**
  - In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
- **Increased Intraocular Pressure**
  - Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

- Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

Please see accompanying full Prescribing Information for more information.

If you have any questions, please reach out to:

Chris Binkowski
703-400-9000
chris.binkowski@apellis.com

Thank you, and we look forward to your participation in this event.

Apellis

SYFOVRE®
(pegcetacoplan injection)
15 mg / 0.1 mL